TFAP2C and prostate cancer: In this study, the c-Myc/miR-25-3p/SLC7A11 signaling axis has been found to be mediated by the Transcription Factor AP-2γ (TFAP2C), which can decrease ferroptosis in prostate cancer and promote chemoresistance [55].